Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577559 | 0.88 | MAPK8 (0.43) | MT-CO2NR3C1MEN1RAB9AKMT2A | |
| SCHEMBL5577536 | 0.87 | DRD2 (0.42) | ADRA1DADRA1AADRA1BMEN1KMT2A | |
| SCHEMBL5577480 | 0.87 | MT-CO2 (0.54) | MT-CO2MEN1RAB9AKMT2AOPRL1 | |
| SCHEMBL5577294 | 0.85 | MT-CO2 (0.49) | MT-CO2MEN1RAB9AKMT2AOPRL1 | |
| SCHEMBL5577372 | 0.84 | GPR183 (0.44) | GNRHROPRL1CHRM3 | |
| SCHEMBL5577806 | 0.82 | MT-CO2 (0.45) | MT-CO2MEN1RAB9AKMT2ACHRM3 | |
| SCHEMBL5577537 | 0.82 | MT-CO2 (0.43) | MT-CO2NR3C1MEN1RAB9AKMT2A | |
| SCHEMBL5577459 | 0.82 | MT-CO2 (0.42) | MT-CO2NR3C1MEN1RAB9AKMT2A | |
| SCHEMBL5577723 | 0.79 | MT-CO2 (0.46) | MT-CO2NR3C1MEN1RAB9AKMT2A | |
| SCHEMBL5577846 | 0.78 | MT-CO2 (0.51) | MT-CO2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885ADRA1D 2107/4885ADRA1A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.